Please assess the completion status of the following clinical trial:

Trial Title: Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide written informed consent prior to participating to the study~* Patients with acute leukemia in remission, MDS, and CML in chronic \& accelerated phase~* Patients with HLA identical donor, a serologic (or higher resolution) 6/6 Class I HLA-A and B and molecular Class II DRB1 must be matched.~* Patients with an ECOG performance status score \< 2~* Adequate end organ functions as defined by: Total bilirubin \< 1.5 × ULN, AST and ALT \< 2.5 × ULN, Creatinine \< 1.5 × ULN.~* Female patients of childbearing potential must have a negative serum pregnancy test within 7 days before initiation of study drug.~Exclusion Criteria:~* Acute promyelocytic leukemia (M3)~* Patients with another primary malignancy other than hematologic disease~* Patients with a severe or uncontrolled medical condition (i.e. uncontrolled diabetes, chronic renal disease)~* Patients who are ① pregnancy, ② breast feeding, ③ of childbearing potential without a negative pregnancy test prior to baseline and ④ male or female of childbearing potential unwilling to use barrier contraceptive precautious throughout the trial (post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential)~* Patients with an ECOG performance status score ≥ 2~* Patients with known positivity for HIV; baseline testing for HIV is not required

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- acute GVHD prevention by sirolimus based regimen (Type: EXPERIMENTAL): The investigators will evaluated the primary endpoint and secondary endpoints comparing with historical control, that is used tacrolimus/methotrexate as a GVHD prophylaxis after HLA-matched, related PBSCT.

Based on this trial design, predict the completion outcome and termination type (if applicable).